BBS8 Inhibitors
BBS8 inhibitors are a class of small molecules designed to specifically target and inhibit the function of the Bardet-Biedl syndrome 8 (BBS8) protein, which plays a crucial role in the development and maintenance of cilia. Cilia are slender, hair-like structures found on the surface of many cell types in the human body and are involved in various cellular processes, including sensory perception and signal transduction. BBS8 is part of the BBSome complex, a protein assembly critical for ciliary trafficking and function. Dysregulation of ciliary processes has been linked to a range of genetic disorders, including Bardet-Biedl syndrome (BBS), a rare genetic disorder characterized by a variety of characteristics, including obesity, vision impairment, and kidney dysfunction.
The mechanism of action of BBS8 inhibitors involves targeting the BBS8 protein to disrupt its normal function within the BBSome complex. By binding to BBS8 or interfering with its interactions with other BBSome components, these inhibitors hinder the formation or stability of the BBSome complex itself. This disruption has downstream effects on ciliary trafficking and signaling pathways associated with cilia-dependent processes. In essence, BBS8 inhibitors act as molecular tools to investigate the role of the BBSome and ciliary function in cellular and physiological processes.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $115.00 $415.00 | 11 | |
Vemurafenib inhibits BBs8 by targeting its mutated form, which is commonly found in melanoma. It binds to the active site, blocking downstream signaling in the MAPK pathway, thereby suppressing cell proliferation. | ||||||
Dabrafenib | 1195765-45-7 | sc-364477 sc-364477A sc-364477B sc-364477C sc-364477D | 5 mg 25 mg 50 mg 100 mg 10 g | $138.00 $255.00 $273.00 $403.00 $12240.00 | 6 | |
Dabrafenib is a selective BBs8 inhibitor used in the research of melanoma. It binds to the active form of mutated BBs8, inhibiting the MAPK pathway and preventing cancer cell growth. | ||||||
Encorafenib | 1269440-17-6 | sc-507422 | 1 mg | $115.00 | ||
Encorafenib selectively inhibits mutated BBs8, primarily in melanoma. It disrupts the constitutive MAPK pathway signaling in cancer cells, inhibiting their proliferation. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that targets BBs8 and other kinases. It inhibits angiogenesis and cell proliferation in various cancers by blocking multiple signaling pathways. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Regorafenib is a multi-kinase inhibitor that targets BBs8 among other kinases. It acts by inhibiting angiogenesis, cell proliferation, and tumor growth in different cancer types. | ||||||
TAK 632 | 1228591-30-7 | sc-473801 | 5 mg | $224.00 | ||
TAK-632 is a selective BBs8 inhibitor that targets the mutated form of BBs8. It suppresses the MAPK pathway, inhibiting cancer cell growth. | ||||||
CEP 32496 | 1188910-76-0 | sc-504760 | 2.5 mg | $430.00 | ||
CEP 32496 is a BBs8 inhibitor designed to target the mutated form of BBs8. It blocks the MAPK pathway, reducing cancer cell proliferation. | ||||||